Pharmacy benefit companies negotiate rebates from drug companies, which they pass to health plan sponsors. Health plan sponsors then use the rebates to make pharmacy benefits more affordable for patients.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that Katie Payne has been appointed Senior Vice President of Strategic Communications. In her role, Ms. Payne will be responsible for leading PCMA’s communications function and will oversee the
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Officer of Inspector General report (OIG) on prescription drug rebates in Medicare Part D. “Today’s OIG report
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
Last week, the U.S. House Ways and Means Committee Health Subcommittee held a hearing on “Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets.” During the hearing, Congressman Kevin Hern (R-OK) shared that, as a former business owner, he was
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
©2024 PCMA. All Rights Reserved.
